Prodrugs of Quercetin and Resveratrol: A Strategy Under Development
The biochemical activities of plant flavonoids and stilbenoids point to many health-related applications, hampered however by a low bioavailability associated with rapid metabolic modification. A possible approach to overcome this obstacle is the development of prodrugs. In this review we provide some background information and summarize the efforts made so far to obtain suitable precursors of the two best known model polyphenols belonging to the classes just mentioned, quercetin and resveratrol. Prodrug design needs to take into account two key aspects: the nature of the chemical bond linking the core molecule to the protecting substituent, and the substituent itself, which can impart desirable physico-chemical properties. Only recently a systematic study of the several possible combinations has begun. Most bond systems tested so far appear to be either too stable or too unstable under physiological conditions. A range of substituent moieties is available, allowing the modulation of properties such as water solubility and the ability to permeate biomembranes. Work so far has been largely performed in vitro, and more in vivo experiments are definitely needed for a reliable assessment of the potentialities of the classes of prodrugs produced so far and of those still awaiting creation.
No Supplementary Data
No Article Media
Document Type: Research Article
Publication date: January 1, 2014
More about this publication?
- Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism and disposition. The journal serves as an international forum for the publication of timely reviews in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments. The journal covers the following areas:
In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; recent developments for the identification of drug metabolites and adducts.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites